




RealRate

PHARMACEUTICAL 2020

Cumberland Pharmaceuticals INC
Rank 167 of 363



The relative strengths and weaknesses of Cumberland Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cumberland Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Cumberland Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 258%, being 20% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	50,163
Cost of Goods Sold	8,752
Intangible Assets	31,802
Liabilities, Current	24,150
Liabilities, Non-Current	10,814
Other Assets	21,836
Other Compr. Net Income	0
Other Expenses	25,730
Other Liabilities	18,500
Other Net Income	243
Other Revenues	47,534
Property and Equipment	748
Research and Development	6,479
Selling, General and Administrative Expense	10,362

Output Variable	Value in 1000 USD
Assets	104,549
Liabilities	53,464
Expenses	51,324
Revenues	47,534
Stockholders Equity	51,085
Net Income	-3,547
Comprehensive Net Income	-3,547
BaseVar	128,557
ECR before Limited Liability	136%
Economic Capital Ratio	258%